Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia

Modern Pathology

Volumn 20, Issue 12, 2007, Pages 1238-1244

  Brody, Jonathan R ^a   Witkiewicz, Agnes ^a   Williams, Timothy K ^a   Kadkol, Shrihari S ^b   Cozzitorto, Joseph ^a   Durkan, Brandice ^a   Pasternack, Gary R ^c   Yeo, Charles J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intraductal papillary mucinous neoplasms; Pancreatic ductal adenocarcinoma; Poorly differentiated pancreatic adenocarcinomas; pp32 (ANP32A); Protein expression; Tumor suppressor

Indexed keywords

K RAS PROTEIN; NUCLEAR PHOSPHOPROTEIN 32; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DYSPLASIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; PANCREAS ACINUS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PANCREAS DYSPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHOSPHOPROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 36249024805     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800974     Document Type: Article

References (17)

1. Kadkol SS, Brody JR, Epstein JI, et al. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate 1998;34:231-237.
2. Kadkol SS, El Naga GA, Brody JR, et al. Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 2001;68:65-73.
3. Brody JR, Kadkol SS, Mahmoud MA, et al. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 1999;274:20053-20055.
4. Chen TH, Brody JR, Romantsev FE, et al. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol Biol Cell 1996;7:2045-2056.
5. Bai J, Brody JR, Kadkol SS, et al. Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene 2001;20:2153-2160.
6. Adegbola O, Pasternack GR. Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis. J Biol Chem 2005;280:15497-15502.
7. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-3130.
8. Brennan CM, Gallouzi IE, Steitz JA. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 2000;151:1-14.
9. Lopez de Silanes I, Lal A, Gorospe M. HuR: posttranscriptional paths to malignancy. RNA Biol 2005;2:11-13.
10. Fan Z, Zhang H, Zhang Q. Tumor suppressor pp32 represses cell growth through inhibition of transcription by blocking acetylation and phosphorylation of histone H3 and initiating its proapoptotic activity. Cell Death Differ 2006;13:1485-1494.
11. Seo SB, Macfarlan T, McNamara P, et al. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002;277:14005-14010.
12. Kadkol SS, Brody JR, Pevsner J, et al. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nat Med 1999;5:275-279.
13. Brody JR, Kadkol SS, Hauer MC, et al. pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol 2004;164:273-283.
14. Malek SN, Katumuluwa AI, Pasternack GR. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins. J Biol Chem 1990;265:13400-13409.
15. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-1211.
16. Feldmann G, Beaty R, Hruban RH, et al. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007;14:224-232.
17. Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997;226:491-498; discussion 498-500.